Skip to Content

AstraZeneca PLC AZN Stock Quote

| Rating as of


Last close prices updated as of Jun 02, 2023, 5:06 PM BST | GBX
  • Last Close 117.48
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Growth
  • Day Range 11,530.00  –  11,754.00
  • Year Range 9,399.00  –  12,828.45
  • Market Cap 18.2077 Tril
  • Volume / Avg 1.5 Mil /  1.9 Mil
  • Price / Sales 5.17
  • Price / Book 6.29
  • Forward Div Yield 2.04%
  • Trailing Div Yield 0.02%

Morningstar‘s Stock Analysis AZN

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


AstraZeneca Earnings: Core Product Growth and Strong Pipeline Advancement Offset Lost COVID-19 Sales

Damien Conover Sector Director

Analyst Note

| Damien Conover |

AstraZeneca reported solid first-quarter results slightly above our expectations, but we don’t expect any major change to our fair value estimate. While COVID-19 product sales were down as expected with the pandemic receding, core products continue to post solid growth while the pipeline is making excellent strides to reinforce the firm’s wide moat.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics AZN

Company Profile AZN

Business Description

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one-third of its sales.

1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge, CB2 0AA, GBR
Industry Drug Manufacturers - General
Employees 83,500

Related Articles AZN

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of AZN’s competitive advantage.

AstraZeneca PLC


Bristol-Myers Squibb Co


Eli Lilly and Co


Merck & Co Inc

+$78.00 (0.67%) +$0.98 (1.52%) +$5.84 (1.34%) +$1.59 (1.43%)
Market Cap
18.21 Tril137.94 Bil419.89 Bil285.51 Bil
Drug Manufacturers - General Drug Manufacturers - General Drug Manufacturers - General Drug Manufacturers - General

* Trading data in this section is delayed by at least 15 minutes.

FAQs for AstraZeneca PLC Stock

Yes. AZN has a forward dividend yield of 2.05%. See AZN’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

AZN’s market cap is 18.21 Tril.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

AZN’s stock style is Large Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

AZN’s price/sales is 5.00.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

AZN’s price/forward earnings is 46.53.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

AZN’s price/book is 6.26.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See AZN’s valuation ratios compared to the Market Index.

AZN’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare AZN’s historical performance against its industry peers and the overall market.